Illumina has acquired Fluent BioSciences, enhancing its single-cell analysis and multiomics capabilities. Fluent's innovative technology, including the PIPseq V system, offers cost-effective and scalable solutions, strengthening Illumina's market position and growth strategy.

Kazia Therapeutics reports a 33% improvement in overall survival for newly diagnosed glioblastoma patients using paxalisib in a Phase 2/3 study. Kazia to discuss accelerated FDA approval.

Mastercard shares decline as BofA Securities downgrades the stock amid broader market challenges. In another development, the company has collaborated with Datapro to expand Cross-Border Services in Latin America and the Caribbean.

Virpax Pharmaceuticals reports positive results from a Swine Model pilot study of Probudur. Shares surged 169.8% on strong volume. Probudur showed a long-term, slow-release profile with no adverse effects in preclinical trials.